Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A 6-week recruitment burst at Aga Khan University in Pakistan led the way as COPCOV enrolment broke 1600 participants. Led by MORU, COPCOV is the world’s largest trial trying to determine if hydroxychloroquine and chloroquine prevent COVID-19.

Professor M. Asim Beg and the COPCOV team at Aga Khan University in Pakistan © Asim Beg

"As of COB 29 July, COPCOV has now recruited 1637 participants -- making it the largest pre-exposure prophylaxis study in the world! There is still a way to go, as there remains so much potential in this study, but this is a fantastic milestone. Congratulations, everyone!" said COPCOV Co-PI Dr Will Schilling.

Funded by Wellcome and led by MORU, COPCOV is currently recruiting in Indonesia, Kenya, Zambia, Benin, Côte d’Ivoire and Mali. The global study hopes to open in the coming weeks new study sites in Benin, Ethiopia, Indonesia, Kenya, Nepal and Niger.

Recruitment into the COPCOV study at Aga Khan University slowed earlier in the year due to high COVID-19 vaccination coverage among healthcare worker staff. Following a change in recruitment strategy, the team pivoted to a community-based approach. Although this new approach presented many challenges, a tremendous effort from all those involved led, in less than six weeks, to 381 participants being recruited into COPCOV. This brought the total number of participants recruited at the site to 399 and marks a COPCOV milestone as Aga Khan becomes the first site to hit their recruitment target (400 could not be achieved due one study drug kit being damaged).

A huge congratulation to Professor M. Asim Beg (4th from left) and his team (shown celebrating their achievement 20 July) on this truly fantastic effort. 

-  James Callery, on behalf of the COPCOV team, with thanks to Asim Beg for photo.

Similar stories

Congratulations new Associate Professors

Following the meeting of the Medical Sciences Divisional Committee to consider applications for the conferral of the title of Associate Professor, we are pleased to announce that Rashan Haniffa, Dorcas Kamuya, Isabella Oyier, Le Van Tan and Timothy Walker have been awarded the title Associate Professor

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of ‘fake news’.

Recruitment surges in COPCOV COVID-19 prevention study

As high COVID-19 daily cases and highly transmissible variants risk overwhelming countries’ healthcare systems, COPCOV, the world’s last-standing large prophylaxis RCT, faces tight timelines to determine whether chloroquine/ hydroxychloroquine prevents COVID-19

Simple blood tests may help improve malaria diagnosis in clinical studies

About one-third of children diagnosed with severe malaria may instead have an alternative cause of illness, but simple blood tests could help researchers distinguish between the two and speed up research on new treatments.

ASM Editor in conversation with Nick White

Malaria continues to be a major killer, particularly in sub-Saharan Africa, affecting the world’s most vulnerable populations with more than 500,000 deaths per year, most of them African children. Emergence of resistance to antimalarial drugs is major public health issue. American Society for Microbiology Editor Dr Cesar Arias discusses with Professor Sir Nick White the latest information on this rapidly evolving field.

AMR and scrub typhus among Chiangrai Unit's research priorities

Which infections are most common in the Chiangrai region? How should we treat them and how can we improve diagnostic? Which strategies are most effective in directing antibiotic treatment? Blog by Carlo Perrone, research physician based at the Chiang Rai Clinical Research Unit in Chiangrai, Thailand.